RECURRENT BRAIN METASTASES AFTER RADIATION THERAPY: CRITERIA FOR PHASE 2B STUDY TO ESTABLISH IMAGE INTERPRETATION CLRM-02. TRIAL IN PROGRESS: A PROSPECTIVE, MULTICENTER GROUP. Our utilization of multiple vulnerability signatures in a GUST trial demonstrated that TCGA GBM patients labeled 56% of all cases into at least one “high vulnerability” group. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. © The Author(s) 2021. Published by Oxford University Press, the Society for Neuro-Oncology and the European Association of Neuro-Oncology. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.